Lorazepam

Results: 466



#Item
411NDA[removed]S-014 & S-016 NDA[removed]S-008 & S-009 NDA[removed]S-003 & S-005 FDA Final Labeling Text dated[removed]Page 1 HIGHLIGHTS OF PRESCRIBING INFORMATION

NDA[removed]S-014 & S-016 NDA[removed]S-008 & S-009 NDA[removed]S-003 & S-005 FDA Final Labeling Text dated[removed]Page 1 HIGHLIGHTS OF PRESCRIBING INFORMATION

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-09-27 15:15:17
412Coly-Mycin® M Parenteral (Colistimethate for Injection, USP) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ColyMycin M and other antibacterial drugs, Coly-Mycin M should be used

Coly-Mycin® M Parenteral (Colistimethate for Injection, USP) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ColyMycin M and other antibacterial drugs, Coly-Mycin M should be used

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-03-08 13:44:17
413___________________  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Feraheme safely and effectively. See full prescribing information for Feraheme.

___________________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Feraheme safely and effectively. See full prescribing information for Feraheme.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-12-04 17:58:17
414Morbidity and Mortality Weekly Report Weekly / Vol[removed]No. 23 June 18, 2010  Emergency Department Visits Involving Nonmedical Use of Selected

Morbidity and Mortality Weekly Report Weekly / Vol[removed]No. 23 June 18, 2010 Emergency Department Visits Involving Nonmedical Use of Selected

Add to Reading List

Source URL: www.cdc.gov

Language: English - Date: 2010-06-17 13:06:03
415HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Ferrlecit® safely and effectively. See full prescribing information for Ferrlecit.  Known hypersensitivity to sodiu

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Ferrlecit® safely and effectively. See full prescribing information for Ferrlecit. Known hypersensitivity to sodiu

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-08-26 14:56:45
416CEREBYX®  (Fosphenytoin Sodium Injection) WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES The rate of intravenous CEREBYX administration should not exceed 150 mg phenytoin

CEREBYX® (Fosphenytoin Sodium Injection) WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH RAPID INFUSION RATES The rate of intravenous CEREBYX administration should not exceed 150 mg phenytoin

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-06-17 15:07:05
417Recognition and Management of Pesticide Poisonings

Recognition and Management of Pesticide Poisonings

Add to Reading List

Source URL: www.epa.gov

Language: English - Date: 2012-05-23 10:19:24
418HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TORISEL® safely and effectively. See full prescribing information for TORISEL.  •

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TORISEL® safely and effectively. See full prescribing information for TORISEL. •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-06-16 22:21:20
419HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION

Add to Reading List

Source URL: www.fda.gov

Language: English
420Federal Register / Vol. 76, No[removed]Wesnesday, May 4, [removed]Notices Administration approval, takes at least two years. In addition to the regulatory hurdles facing a potential entrant, manufacturing difficulties in pro

Federal Register / Vol. 76, No[removed]Wesnesday, May 4, [removed]Notices Administration approval, takes at least two years. In addition to the regulatory hurdles facing a potential entrant, manufacturing difficulties in pro

Add to Reading List

Source URL: www.gpo.gov

Language: English - Date: 2013-05-23 12:04:25